DNA methylation profiling predicts postsurgical regrowth in SF1-lineage nonfunctioning pituitary neuroendocrine tumors
Open Access
- 10 December 2025
- journal article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 28 (3) , 728-740
Abstract
Background: Nonfunctioning pituitary neuroendocrine tumors (NFPitNETs) account for ∼30-35% of PitNETs; ∼75% arise from the SF1 lineage. Recurrence remains common despite resection (∼30% in 10 years), and routine histopathology/IHC has limited value in predicting recurrence risk. This study evaluated whether DNA methylation profiling improves recurrence risk stratification. Materials and Methods: Genome-wide tissue methylation (Illumina EPIC v1, 850K) was analyzed in 117 retrospective NFPitNETs with clinical and imaging follow-up. Unsupervised consensus clustering defined methylation-based subgroups, followed by supervised differential methylation analysis to identify cluster-specific differentially methylated probes (DMPs). A classifier was trained using these signatures, with predicted subgroup memberships correlated with regrowth and progression-free survival (PFS). To ensure reliable estimations, longitudinal mixed-effects models were restricted to the interval of model stability (∼9 years), reflecting cohort follow-up. External validation was performed in 3 independent cohorts. Results: Five clusters (k1-k5) emerged: 4 SF1-positive-predominant (k1, k2, k3, and k5) and 1 TPIT/PIT1-enriched NFPitNETs (k4). Among the 562 DMPs, many mapped to genes regulating cell-cycle and immune pathways. Compared with k1-k2, k3, k4, and k5 possessed significantly higher recurrence risk. Within SF1-lineage tumors, k3 exhibited postoperative tumor-volume expansion beginning at ∼6 years. The methylation-based classifier achieved ∼97% accuracy in assigning clusters and maintained prognostic separation across independent cohorts. Conclusions: DNA methylation profiling identifies biologically and clinically distinct NFPitNET subgroups, particularly within the SF1 lineage, and may enhance prediction of recurrence risk. Prospective validation and demonstration of clinical utility are warranted to support integration into precision management workflows.Keywords
Funding Information
- Novo Nordisk Fonden
- Hartmann Fonden
- Tornøes og Høyrups Fond
- Beckett-Fonden, Aase og Ejnar Danielsens Fond
- Odense Universitetshospital
This publication has 40 references indexed in Scilit:
- Genome-wide methylation profiling differentiates benign from aggressive and metastatic pituitary neuroendocrine tumorsActa Neuropathologica, 2024
- Postsurgical outcomes of nonfunctioning pituitary adenomas: a patient-level meta-analysisPituitary, 2023
- Diagnostic, Prognostic, and Predictive Role of Ki67 Proliferative Index in Neuroendocrine and Endocrine Neoplasms: Past, Present, and FutureEndocrine Pathology, 2023
- Post-operative surveillance for somatotroph, lactotroph and non-functional pituitary adenomas after curative resection: a systematic reviewPituitary, 2022
- Overview of the 2022 WHO Classification of Pituitary TumorsEndocrine Pathology, 2022
- Pangenomic Classification of Pituitary Neuroendocrine TumorsCancer Cell, 2020
- DNA methylation profiling in nonfunctioning pituitary adenomasMolecular and Cellular Endocrinology, 2018
- Diagnosis and Treatment of Pituitary AdenomasJAMA, 2017
- The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence AnalysesCurrent Protocols in Bioinformatics, 2016
- BMP action in the pituitary: Its possible role in modulating somatostatin sensitivity in pituitary tumor cellsMolecular and Cellular Endocrinology, 2011